A multi-organizational consensus report establishes practical guidelines for using GLP-1 and dual GLP-1/GIP receptor agonists in type 1 diabetes, despite lacking formal regulatory approval for this indication. The guidelines address safety concerns including hypoglycemia and hyperglycemia-related ketosis risks while acknowledging these agents' proven benefits in weight loss, improved glucose regulation, and cardiovascular protection. This development represents a significant shift in diabetes care philosophy. Type 1 diabetes has traditionally been viewed as solely requiring insulin therapy, but the pleiotropic effects of incretin-based therapies are challenging this paradigm. The consensus acknowledges a growing clinical reality: patients with type 1 diabetes are already accessing these medications through obesity indications, often without proper medical oversight. The safety framework becomes crucial given that type 1 patients lack endogenous insulin production, making them more vulnerable to ketosis when glucose-lowering medications are introduced. While larger randomized trials continue, this expert guidance fills a critical gap between emerging therapeutic potential and regulatory lag. The endorsement by major diabetes organizations signals growing confidence in expanding therapeutic options beyond traditional insulin-centric approaches for type 1 diabetes management.